MAGE-A1, MAGE-A3, and NY-ESO-1 can be upregulated on neuroblastoma cells to facilitate cytotoxic T lymphocyte-mediated tumor cell killing

Cancer Immunology, Immunotherapy

Volumn 60, Issue 9, 2011, Pages 1299-1307

  Bao, Lei ^a   Dunham, Kimberly ^a   Lucas, Kenneth ^a  

^a PENN STATE CHILDREN S HOSPITAL   (United States)

Author keywords

Cancer testis antigens; Decitabine; Interferon ; MHC molecules; Neuroblastoma

Indexed keywords

5 AZA 2' DEOXYCYTIDINE; CANCER TESTIS ANTIGEN; GAMMA INTERFERON; MAJOR HISTOCOMPATIBILITY ANTIGEN; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 1; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 2; MELANOMA ANTIGEN 1; MELANOMA ANTIGEN 3; NY ESO 1 ANTIGEN;

ANTIGEN EXPRESSION; ANTIGEN RECOGNITION; ANTIGEN SPECIFICITY; ANTINEOPLASTIC ACTIVITY; ARTICLE; CELL KILLING; CONTROLLED STUDY; CYTOFLUOROMETRY; CYTOTOXIC T LYMPHOCYTE; DENDRITIC CELL; DOWN REGULATION; GLIOBLASTOMA; HUMAN; HUMAN CELL; NEUROBLASTOMA; NEUROBLASTOMA CELL; PERIPHERAL BLOOD MONONUCLEAR CELL; PRIORITY JOURNAL; TUMOR CELL; TUMOR CELL LINE; TUMOR IMMUNITY; UPREGULATION; VOLUNTEER;

ANTIGENS, NEOPLASM; AZACITIDINE; CELL LINE, TUMOR; HUMANS; INTERFERON-GAMMA; MELANOMA-SPECIFIC ANTIGENS; MEMBRANE PROTEINS; NEOPLASM PROTEINS; NEUROBLASTOMA; T-LYMPHOCYTES, CYTOTOXIC; UP-REGULATION;

EID: 80054689372     PISSN: 03407004     EISSN: 14320851     Source Type: Journal    
DOI: 10.1007/s00262-011-1037-z     Document Type: Article

References (45)

1. Brodeur GM (2003) Neuroblastoma: biological insights into a clinical enigma. Nat Rev Cancer 3:203-216 (Pubitemid 37328872)
2. Ploegh HL (1998) Viral strategies of immune evasion. Science 280:248-253 (Pubitemid 28178062)
3. Wolfl M, Jungbluth AA, Garrido F, Cabrera T, Meyen-Southard S, Spitz R, Ernestus K, Berthold F (2005) Expression of MHC class I, MHC class II, and cancer germline antigens in neuroblastoma. Cancer Immunol Immunother 54:400-406 (Pubitemid 40238934)
4. Jungbluth AA, Antonescu CR, Busam KJ, Iversen K, Kolb D, Coplan K, Chen YT, Stockert E, Ladanyi M, Old LJ (2001) Monophasic and biphasic synovial sarcomas abundantly express cancer/testis antigen NY-ESO-1 but not MAGE-A1 or CT7. Int J Cancer 94:252-256 (Pubitemid 32911421)
5. Barrow C, Browning J, MacGregor D, Davis ID, Sturrock S, Jungbluth AA, Cebon J (2006) Tumor antigen expression in melanoma varies according to antigen and stage. Clin Cancer Res. 12:764-771 (Pubitemid 43259856)
6. Chianese-Bullock KA, Pressley J, Garbee C, Hibbitts S, Murphy C, Yamshchikov G, Petroni GR, Bissonette EA, Neese PY, Grosh WW et al (2005) MAGE-A1-, MAGE-A10-, and gp100-derived peptides are immunogenic when combined with granulocyte-macrophage colony-stimulating factor and montanide ISA-51 adjuvant and administered as part of a multipeptide vaccine for melanoma. J Immunol 174:3080-3086 (Pubitemid 40279730)
7. Carrasco J, Van Pel A, Neyns B, Lethe B, Brasseur F, Renkvist N, van der Bruggen P, van Baren N, Paulus R, Thielemans K et al (2008) Vaccination of a melanoma patient with mature dendritic cells pulsed with MAGE-3 peptides triggers the activity of nonvaccine anti-tumor cells. J Immunol 180:3585-3593
8. Thurner B, Haendle I, Roder C, Dieckmann D, Keikavoussi P, Jonuleit H, Bender A, Maczek C, Schreiner D, von den Driesch P et al (1999) Vaccination with mage-3A1 peptide-pulsed mature, monocyte-derived dendritic cells expands specific cytotoxic T cells and induces regression of some metastases in advanced stage IV melanoma. J Exp Med 190:1669-1678 (Pubitemid 30002348)
9. Jager E, Gnjatic S, Nagata Y, Stockert E, Jager D, Karbach J, Neumann A, Rieckenberg J, Chen YT, Ritter G et al (2000) Induction of primary NY-ESO-1 immunity: CD8+ T lymphocyte and antibody responses in peptide-vaccinated patients with NY-ESO-1+ cancers. Proc Natl Acad Sci USA 97:12198-12203
10. Chen Q, Jackson H, Shackleton M, Parente P, Hopkins W, Sturrock S, MacGregor D, Maraskovsky E, Tai TY, Dimopoulos N et al (2005) Characterization of antigen-specific CD8+ T lymphocyte responses in skin and peripheral blood following intradermal peptide vaccination. Cancer Immun 5:5
11. Bender A, Karbach J, Neumann A, Jager D, Al-Batran SE, Atmaca A, Weidmann E, Biskamp M, Gnjatic S, Pan L et al (2007) LUD 00-009: phase 1 study of intensive course immunization with NYESO-1 peptides in HLA-A2 positive patients with NY-ESO-1- expressing cancer. Cancer Immun 7:16
12. Mackensen A, Herbst B, Chen JL, Kohler G, Noppen C, Herr W, Spagnoli GC, Cerundolo V, Lindemann A (2000) Phase I study in melanoma patients of a vaccine with peptide-pulsed dendritic cells generated in vitro from CD34(+) hematopoietic progenitor cells. Int J Cancer 86:385-392 (Pubitemid 30187500)
13. Razin A, Riggs AD (1980) DNA methylation and gene function. Science 210:604-610
14. Merlo A, Herman JG, Mao L, Lee DJ, Gabrielson E, Burger PC, Baylin SB, Sidransky D (1995) 5' CpG island methylation is associated with transcriptional silencing of the tumour suppressor p16/ CDKN2/MTS1 in human cancers. Nat Med 1:686-692
15. Yang H, Hoshino K, Sanchez-Gonzalez B, Kantarjian H, Garcia- Manero G (2005) Antileukemia activity of the combination of 5- aza-2'-deoxycytidine with valproic acid. Leuk Res 29:739-748 (Pubitemid 40779480)
16. Garcia-Manero G, Gore SD (2005) Future directions for the use of hypomethylating agents. Semin Hematol 42:S50-S59 (Pubitemid 40961873)
17. Issa JP, Gharibyan V, Cortes J, Jelinek J, Morris G, Verstovsek S, Talpaz M, Garcia-Manero G, Kantarjian HM (2005) Phase II study of low-dose decitabine in patients with chronic myelogenous leukemia resistant to imatinib mesylate. J Clin Oncol 23:3948-3956 (Pubitemid 46218698)
18. Adair SJ, Hogan K (2009) Treatment of ovarian cancer cell lines with 5-aza-2'-deoxycytidine upregulates the expression of cancer-testis antigens and class I major histocompatibility complex-encoded molecules. Cancer Immunol Immunother 58:589-601
19. Schrump DS, Fischette MR, Nguyen DM, Zhao M, Li X, Kunst TF, Hancox A, Hong JA, Chen GA, Pishchik V et al (2006) Phase I study of decitabine-mediated gene expression in patients with cancers involving the lungs, esophagus, or pleura. Clin Cancer Res 12:5777-5785 (Pubitemid 44629609)
20. Serrano A, Tanzarella S, Lionello I, Mendez R, Traversari C, Ruiz-Cabello F, Garrido F (2001) Rexpression of HLA class I antigens and restoration of antigen-specific CTL response in mela noma cells following 5-aza-2′l- deoxycytidine treatment. Int J Cancer 94:243-251 (Pubitemid 32911420)
21. Sigalotti L, Altomonte M, Colizzi F, Degan M, Rupolo M, Zagonel V, Pinto A, Gattei V, Maio M (2003) 5-Aza-2′-deoxycytidine (decitabine) treatment of hematopoietic malignancies: a multimechanism therapeutic approach? Blood 101:4644-4646; discussion 4645-4646 (Pubitemid 36857844)
22. Natsume A, Wakabayashi T, Tsujimura K, Shimato S, Ito M, Kuzushima K, Kondo Y, Sekido Y, Kawatsura H, Narita Y, Yoshida J (2008) The DNA demethylating agent 5-aza-2′-deoxycytidine activates NY-ESO-1 antigenicity in orthotopic human glioma. Int J Cancer 122:2542-2553 (Pubitemid 351590488)
23. Gross N, Beck D, Favre S, Carrel S (1987) In vitro antigenic modulation of human neuroblastoma cells induced by IFN-gamma, retinoic acid and dibutyryl cyclic AMP. Int J Cancer 39:521-529 (Pubitemid 17059783)
24. Ponzoni M, Guarnaccia F, Corrias MV, Cornaglia-Ferraris P (1993) Uncoordinate induction and differential regulation of HLA class-I and class-II expression by gamma-interferon in differentiating human neuroblastoma cells. Int J Cancer 55:817-823 (Pubitemid 23354900)
25. Su S, Vivier RG, Dickson MC, Thomas N, Kendrick MK, Williamson NM, Anson JG, Houston JG, Craig FF (1997) High-throughput RT-PCR analysis of multiple transcripts using a microplate RNA isolation procedure. Biotechniques 22:1107-1113 (Pubitemid 27248984)
26. Tajima K, Obata Y, Tamaki H, Yoshida M, Chen YT, Scanlan MJ, Old LJ, Kuwano H, Takahashi T, Mitsudomi T (2003) Expression of cancer/testis (CT) antigens in lung cancer. Lung Cancer 42:23-33 (Pubitemid 37153132)
27. Gaugler B, Van den Eynde B, van der Bruggen P, Romero P, Gaforio JJ, De Plaen E, Lethe B, Brasseur F, Boon T (1994) Human gene MAGE-3 codes for an antigen recognized on a melanoma by autologous cytolytic T lymphocytes. J Exp Med 179:921-930 (Pubitemid 24065650)
28. Riddell SR, Greenberg PD (1990) The use of anti-CD3 and anti- CD28 monoclonal antibodies to clone and expand human antigenspecific T cells. J Immunol Methods 128:189-201 (Pubitemid 20120262)
29. Levine BL, Bernstein WB, Aronson NE, Schlienger K, Cotte J, Perfetto S, Humphries MJ, Ratto-Kim S, Birx DL, Steffens C et al (2002) Adoptive transfer of costimulated CD4+ T cells induces expansion of peripheral T cells and decreased CCR5 expression in HIV infection. Nat Med 8:47-53 (Pubitemid 34101728)
30. Sun Q, Burton RL, Dai LJ, Britt WJ, Lucas KG (2000) B lymphoblastoid cell lines as efficient APC to elicit CD8+ T cell responses against a cytomegalovirus antigen. J Immunol 165:4105-4111 (Pubitemid 32057322)
31. Ho WY, Nguyen HN, Wolfl M, Kuball J, Greenberg PD (2006) In vitro methods for generating CD8+ T-cell clones for immunotherapy from the naive repertoire. J Immunol Methods 310:40-52 (Pubitemid 43375974)
32. Teitz T, Wei T, Valentine MB, Vanin EF, Grenet J, Valentine VA, Behm FG, Look AT, Lahti JM, Kidd VJ (2000) Caspase 8 is deleted or silenced preferentially in childhood neuroblastomas with amplification of MYCN. Nat Med 6:529-535 (Pubitemid 30305902)
33. Boon T, Cerottini JC, Van den Eynde B, van der Bruggen P, Van Pel A (1994) Tumor antigens recognized by T lymphocytes. Annu Rev Immunol 12:337-365 (Pubitemid 24140418)
34. Chen YT, Scanlan MJ, Sahin U, Tureci O, Gure AO, Tsang S, Williamson B, Stockert E, Pfreundschuh M, Old LJ (1997) A testicular antigen aberrantly expressed in human cancers detected by autologous antibody screening. Proc Natl Acad Sci USA 94:1914-1918 (Pubitemid 27113936)
35. Vaughan HA, Svobodova S, Macgregor D, Sturrock S, Jungbluth AA, Browning J, Davis ID, Parente P, Chen YT, Stockert E et al (2004) Immunohistochemical and molecular analysis of human melanomas for expression of the human cancer-testis antigens NY-ESO-1 and LAGE-1. Clin Cancer Res 10:8396-8404 (Pubitemid 40053402)
36. Scanlan MJ, Simpson AJ, Old LJ (2004) The cancer/testis genes: review, standardization, and commentary. Cancer Immun 4:1
37. Rodolfo M, Luksch R, Stockert E, Chen YT, Collini P, Ranzani T, Lombardo C, Dalerba P, Rivoltini L, Arienti F et al (2003) Antigen-specific immunity in neuroblastoma patients: antibody and T-cell recognition of NY-ESO-1 tumor antigen. Cancer Res 63:6948-6955 (Pubitemid 37322981)
38. Davis ID, Chen W, Jackson H, Parente P, Shackleton M, Hopkins W, Chen Q, Dimopoulos N, Luke T, Murphy R et al (2004) Recombinant NY-ESO-1 protein with ISCOMATRIX adjuvant induces broad integrated antibody and CD4(+) and CD8(+) T cell responses in humans. Proc Natl Acad Sci USA 101:10697-10702 (Pubitemid 38955805)
39. Fulda S, Debatin KM (2006) 5-Aza-2′-deoxycytidine and IFNgamma cooperate to sensitize for TRAIL-induced apoptosis by upregulating caspase-8. Oncogene 25:5125-5133 (Pubitemid 44285981)
40. Ponzoni M, Lanciotti M, Montaldo PG, Cornaglia-Ferraris P (1991) Gamma-interferon, retinoic acid, and cytosine arabinoside induce neuroblastoma differentiation by different mechanisms. Cell Mol Neurobiol 11:397-413
41. Gross N, Beck D, Favre S (1990) In vitro modulation and relationship between N-myc and HLA class I RNA steady-state levels in human neuroblastoma cells. Cancer Res 50:7532-7536
42. Miller CH, Maher SG, Young HA (2009) Clinical use of interferon- gamma. Ann NY Acad Sci 1182:69-79
43. Wolfl M, Kuball J, Ho WY, Nguyen H, Manley TJ, Bleakley M, Greenberg PD (2007) Activation-induced expression of CD137 permits detection, isolation, and expansion of the full repertoire of CD8+ T cells responding to antigen without requiring knowledge of epitope specificities. Blood 110:201-210 (Pubitemid 47026836)
44. Ramakrishnan R, Assudani D, Nagaraj S, Hunter T, Cho HI, Antonia S, Altiok S, Celis E, Gabrilovich DI (2010) Chemotherapy enhances tumor cell susceptibility to CTL-mediated killing during cancer immunotherapy in mice. J Clin Invest 120:1111-1124
45. Samlowski WE, Leachman SA, Wade M, Cassidy P, Porter-Gill P, Busby L, Wheeler R, Boucher K, Fitzpatrick F, Jones DA, Karpf AR (2005) Evaluation of a 7-day continuous intravenous infusion of decitabine: inhibition of promoter-specific and global genomic DNA methylation. J Clin Oncol 23:3897-3905 (Pubitemid 46218692)